Abstract
Considerable progress is being made in the transfer of genetic material to hematopoietic stem cells. In this chapter we describe how gene transfer is being used to: mark marrow and peripheral blood progenitor cells prior to autologous transplantation, to track their fate on reinfusion and to detect contaminating tumorigenic cells; modulate immunocyte function - important in immunologic disorders and perhaps in cancer therapy; generate tumor vaccines from tumor cells isolated from marrow; correct single gene defects - the 'classical' concept of gene therapy; and finally to modify the drug sensitivity of progenitor cells enabling them to resist the suppressive effects of cytotoxic drugs during cancer therapy and perhaps providing a mechanism for in vivo selection of gene modified cells.
Original language | English (US) |
---|---|
Pages (from-to) | 167-191 |
Number of pages | 25 |
Journal | British Medical Bulletin |
Volume | 51 |
Issue number | 1 |
DOIs | |
State | Published - 1995 |
ASJC Scopus subject areas
- Medicine(all)